Drug Cardiovascular & Metabolism

Xarelto

Payments companies reported to CMS as associated with Xarelto. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$12Massociated payments (2023-2025)

60,873clinicians with associated payments

8companies reporting

By year

2023 $6.6M

2024 $5.1M

2025 $21K

Payments reported as associated with Xarelto, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Cardiovascular Disease $2.9M

Interventional Cardiology $2.3M

Internal Medicine $1.2M

Clinical Cardiac Electrophysiology $626K

Family $554K

Emergency Medicine $474K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Xarelto

These are the largest totals companies reported as associated with Xarelto. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Vinay Hosmane	Wilmington, DE	Cardiovascular Disease	$114,733.23
Joshua Yamamoto	Washington, DC	Cardiovascular Disease	$104,598.52
Matthew Becker	Erie, PA	Interventional Cardiology	$102,549.05
Michael Levine	New Hyde Park, NY	Cardiovascular Disease	$99,832.00
Steven Kang	Oakland, CA	Clinical Cardiac Electrophysiology	$96,224.30
Craig Walker	Houma, LA	Interventional Cardiology	$95,625.43
Sonya Noor	Buffalo, NY	Vascular Surgery	$95,522.13
Ronald Uszenski	Mooresville, NC	Interventional Cardiology	$93,062.73
Shailendra Singh	Allentown, PA	Interventional Cardiology	$85,345.32
Stanley Thompson	Southaven, MS	Emergency Medicine	$85,167.52

Prescribed Xarelto?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.